Market Cap 381.02M
Revenue (ttm) 234.04M
Net Income (ttm) -323.99M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -138.43%
Debt to Equity Ratio -0.13
Volume 4,123,100
Avg Vol 3,110,214
Day's Range N/A - N/A
Shares Out 104.39M
Stochastic %K 47%
Beta 0.90
Analysts Sell
Price Target $8.00
11thestate
11thestate Jun. 11 at 3:03 PM
The $17.25M Revance Therapeutics ($RVNC) settlement deadline is August 28, 2026. If you purchased $RVNC shares between February 29, 2024 and December 6, 2024, you may be eligible. The case alleges Revance misled investors about its business performance and merger discussions with Crown Laboratories before the stock fell sharply. File your claim here: https://11th.com/cases/revance-investor-settlement
0 · Reply
11thestate
11thestate May. 29 at 3:05 PM
FAQ for $RVNC investors Q:What is this settlement about? A: Revance Therapeutics agreed to a $17M settlement over claims the company misled investors about its relationship with Teoxane and the delayed Crown tender offer. Q: Who may qualify? A: Investors who purchased or acquired $RVNC securities between Feb. 29, 2024 and Feb. 6, 2025. Q: What’s the deadline? A: The claim deadline is Aug. 28, 2026. Q: What happened to the stock? A: After disclosures about the Teoxane dispute and revised merger terms, Crown cut its offer price from $6.66/share to $3.10/share. Q: Is my data safe with 11th Estate? A: Security is our top priority. We use bank-level encryption and are SOC2-compliant. We only process the trade data required for the court audit, and your personal financial credentials stay private. Q: What is the fee? A: We work on a 20% success fee. We handle the math, the paperwork, and the filing. If you don't get a payout, you don't pay us a cent. Q: How do I start? A: Just click the link below to submit your claim through our secure portal. https://11th.com/cases/revance-investor-settlement
0 · Reply
11thestate
11thestate May. 11 at 2:44 PM
The $17 million Revance Therapeutics ($RVNC) deadline is August 28, 2026 If you bought shares between February 29, 2024, and February 6, 2025, you are likely eligible for the $17 million recovery fund. This settlement resolves claims that Revance Therapeutics misled investors regarding its Teoxane dispute, delayed Crown tender offer, and related stock-price declines. The stock dropped following the disclosure, and now the company is paying back to impacted shareholders ($0.16 per share). File your claim here: https://11th.com/cases/revance-investor-settlement
0 · Reply
11thestate
11thestate Apr. 27 at 4:05 PM
$RVNC — Updates for the Revance Therapeutics investor settlement The settlement has just received preliminary approval, and you can already submit a claim to get payment. 📌 What happened? Revance allegedly misled investors about the strength and sustainability of its Teoxane partnership and overall sales performance. The issue came to light when a breach notice, stricter contract terms, and financial concerns were disclosed, leading to a reduced acquisition offer and significant pressure on the company’s outlook. ❓ Who qualifies? Buyers of $RVNC between February 29, 2024, and February 6, 2025, inclusive. ➡️ Apply now: https://11th.com/cases/revance-investor-settlement
1 · Reply
BNBComedian
BNBComedian Jul. 23 at 2:28 AM
$RVNC this was a sure thing at $25
0 · Reply
Thebiggerone
Thebiggerone Feb. 14 at 1:10 AM
$RVNC penny land inbound
0 · Reply
TheMAGATrader
TheMAGATrader Feb. 13 at 9:52 PM
$RVNC Hahahahahahah...
0 · Reply
Estimize
Estimize Feb. 10 at 1:27 PM
Wall St is expecting -0.30 EPS for $RVNC Q1 [Reporting 05/08 AMC] http://www.estimize.com/intro/rvnc?chart=historical&metric_name=eps&utm_c
0 · Reply
wrynot
wrynot Feb. 6 at 3:02 PM
$RVNC I’m going to have a $TELL 2.0 delisting ceremony. I hope Foley has to sell his house like Souki.
2 · Reply
AlertsAndNews
AlertsAndNews Feb. 6 at 1:42 PM
$RVNC Crown Laboratories Announces Completion of Acquisition of Revance Therapeutics Currently t-12 halted
0 · Reply
Latest News on RVNC
11thestate
11thestate Jun. 11 at 3:03 PM
The $17.25M Revance Therapeutics ($RVNC) settlement deadline is August 28, 2026. If you purchased $RVNC shares between February 29, 2024 and December 6, 2024, you may be eligible. The case alleges Revance misled investors about its business performance and merger discussions with Crown Laboratories before the stock fell sharply. File your claim here: https://11th.com/cases/revance-investor-settlement
0 · Reply
11thestate
11thestate May. 29 at 3:05 PM
FAQ for $RVNC investors Q:What is this settlement about? A: Revance Therapeutics agreed to a $17M settlement over claims the company misled investors about its relationship with Teoxane and the delayed Crown tender offer. Q: Who may qualify? A: Investors who purchased or acquired $RVNC securities between Feb. 29, 2024 and Feb. 6, 2025. Q: What’s the deadline? A: The claim deadline is Aug. 28, 2026. Q: What happened to the stock? A: After disclosures about the Teoxane dispute and revised merger terms, Crown cut its offer price from $6.66/share to $3.10/share. Q: Is my data safe with 11th Estate? A: Security is our top priority. We use bank-level encryption and are SOC2-compliant. We only process the trade data required for the court audit, and your personal financial credentials stay private. Q: What is the fee? A: We work on a 20% success fee. We handle the math, the paperwork, and the filing. If you don't get a payout, you don't pay us a cent. Q: How do I start? A: Just click the link below to submit your claim through our secure portal. https://11th.com/cases/revance-investor-settlement
0 · Reply
11thestate
11thestate May. 11 at 2:44 PM
The $17 million Revance Therapeutics ($RVNC) deadline is August 28, 2026 If you bought shares between February 29, 2024, and February 6, 2025, you are likely eligible for the $17 million recovery fund. This settlement resolves claims that Revance Therapeutics misled investors regarding its Teoxane dispute, delayed Crown tender offer, and related stock-price declines. The stock dropped following the disclosure, and now the company is paying back to impacted shareholders ($0.16 per share). File your claim here: https://11th.com/cases/revance-investor-settlement
0 · Reply
11thestate
11thestate Apr. 27 at 4:05 PM
$RVNC — Updates for the Revance Therapeutics investor settlement The settlement has just received preliminary approval, and you can already submit a claim to get payment. 📌 What happened? Revance allegedly misled investors about the strength and sustainability of its Teoxane partnership and overall sales performance. The issue came to light when a breach notice, stricter contract terms, and financial concerns were disclosed, leading to a reduced acquisition offer and significant pressure on the company’s outlook. ❓ Who qualifies? Buyers of $RVNC between February 29, 2024, and February 6, 2025, inclusive. ➡️ Apply now: https://11th.com/cases/revance-investor-settlement
1 · Reply
BNBComedian
BNBComedian Jul. 23 at 2:28 AM
$RVNC this was a sure thing at $25
0 · Reply
Thebiggerone
Thebiggerone Feb. 14 at 1:10 AM
$RVNC penny land inbound
0 · Reply
TheMAGATrader
TheMAGATrader Feb. 13 at 9:52 PM
$RVNC Hahahahahahah...
0 · Reply
Estimize
Estimize Feb. 10 at 1:27 PM
Wall St is expecting -0.30 EPS for $RVNC Q1 [Reporting 05/08 AMC] http://www.estimize.com/intro/rvnc?chart=historical&metric_name=eps&utm_c
0 · Reply
wrynot
wrynot Feb. 6 at 3:02 PM
$RVNC I’m going to have a $TELL 2.0 delisting ceremony. I hope Foley has to sell his house like Souki.
2 · Reply
AlertsAndNews
AlertsAndNews Feb. 6 at 1:42 PM
$RVNC Crown Laboratories Announces Completion of Acquisition of Revance Therapeutics Currently t-12 halted
0 · Reply
HellenJune
HellenJune Feb. 6 at 1:07 PM
https://www.prnewswire.com/news-releases/the-gross-law-firm-notifies-shareholders-of-revance-therapeutics-incrvnc-of-a-class-action-lawsuit-and-an-upcoming-deadline-302369534.html $RVNC
0 · Reply
Mergerbrief
Mergerbrief Feb. 4 at 1:23 PM
$RVNC / Crown Labs - Tender Offer Expires Today MergerBrief.com Merger Tracking
0 · Reply
RainyDayFund
RainyDayFund Feb. 4 at 12:20 AM
$RVNC So I guess we have no choice and have to take their measly $3.65 per share?
1 · Reply
valueforme
valueforme Feb. 1 at 10:52 PM
$RVNC This never ending merger is a good reminder that selling right after merger announcement is the safest way to react
0 · Reply
swingingtech
swingingtech Jan. 24 at 12:51 AM
$RVNC https://wallstreetwaves.com/revance-therapeutics-investors-can-now-take-the-lead-in-securities-fraud-lawsuit-following-losses/
1 · Reply
Miok
Miok Jan. 21 at 4:58 PM
$DRMA $RVNC Crown Laboratories and Revance Amend the A&R Merger Agreement to Increase Offer Price to $3.65 per Share and Extend Existing Tender Offer
0 · Reply
RonIsWrong
RonIsWrong Jan. 21 at 2:04 PM
$RVNC Crown Laboratories hikes offer price for Revance to $3.65/share, extends existing tender offer
0 · Reply
ganduseph
ganduseph Jan. 17 at 2:10 PM
$RVNC Crown offering $3.65 now. Interesting.
1 · Reply